ReviewOncogene2000
The role of prolactin and growth hormone in breast cancer.
Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 107 citations in OpenAlex.
- The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.Cell communication and signaling : CCS · 2024Review
- Metastases to the pituitary gland: insights from the German pituitary tumor registry.Pituitary · 2023Article
- Early Investigations of 20-kDa Human Placental GH Show Promise.Endocrine, metabolic & immune disorders drug targets · 2023Article
- Mice with gene alterations in the GH and IGF family.Pituitary · 2022Review
- Review
- The Effects of 20-kDa Human Placental GH in Male and Female GH-deficient Mice: An Improved Human GH?Endocrinology · 2020Article
- Sexual dimorphism in solid and hematological malignancies.Seminars in immunopathology · 2019Review
- Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.Oncotarget · 2017Article
- Article
- Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.Oncotarget · 2016Article
- The prolactin receptor: Diverse and emerging roles in pathophysiology.Journal of clinical & translational endocrinology · 2015Review
- Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13.Breast cancer research : BCR · 2014Article
- Article
- Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.PloS one · 2014Article
- Male breast carcinoma: increased awareness needed.Breast cancer research : BCR · 2011Review
- Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia.The European journal of neuroscience · 2011Article
- Short-term administration of rhGH increases markers of cellular proliferation but not milk protein gene expression in normal lactating women.Physiological genomics · 2011Article
- Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis.The Journal of clinical investigation · 2010Article
- Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.Journal of molecular endocrinology · 2010Article
- The Pit-1/Pou1f1 transcription factor regulates and correlates with prolactin expression in human breast cell lines and tumors.Endocrine-related cancer · 2010Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review will focus on the role for prolactin (PRL) and growth hormone (GH) in mammary tumor formation. Much attention has previously been focused on circulating levels of GH/PRL in relation to mammary tumor formation. We will review data demonstrating that these ligands also could be produced locally in different organs, including the mammary gland and mammary tumors, and suggest that this local production may be of importance for pathological conditions. We will also discuss mechanisms for crosstalk between steroids and GH/PRL. A crosstalk between GH- and PRL response is possible at multiple levels. In the human, GH can activate both the prolactin receptor (PRLR) and the growth hormone receptor (GHR). We have demonstrated that activation of the PRLR, but not the GHR, is inducing mammary tumors in transgenic mice. Furthermore, the elevated levels of insulin-like growth factor 1 (IGF-I) seen in the GHR activating transgenic mice is not sufficient for tumor induction. The induced tumors express functionally active prolactin that could be of importance for the tumor formation. Paracrine/aurocrine stimulation by PRL may be more important than PRL transported via the circulation. In women, the role for stimulation of the PRLR and/or the GHR in mammary tumor formation has not been proven, although experiments from primates suggest that the PRLR could be of importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.